Chronic Lymphocytic Leukemia Therapeutics Market Drivers Insights 2022

Covid-19 Analysis on Chronic Lymphocytic Leukemia Therapeutics Market

Each aspect of healthcare provision including cancer care has been disrupted by the COVID-19 pandemic. The outbreak of COVID-19 has acted as a significant restraint on the chronic lymphocytic leukemia drugs market in 2020 as supply chains were disrupted due to restrictions on the trade of pharmaceutical ingredients and products across countries. 

COVID 19 is also an infectious condition that causes flu-like symptoms such as fever, cough, and difficulty breathing. The COVID-19 pandemic has disrupted clinical trials and drug supply chains, affecting the most critical parts of the blood cancer drugs industry. Pandemic has directly affected the supply of oncology drugs to cancer patients; it is difficult to administer chemotherapy and certain other treatments outside of a clinic. 

Export-import restrictions and the impact of COVID-19 on two of the world's top producers of active pharmaceutical ingredients (APsssIs) and generics, China and India, are among the issues plaguing pharmaceutical supply chains during this pandemic. The Food and Drug Administration (FDA) declared in February 2020 that the supply chain for important medical products and services imported from China had been disrupted.

The sudden outbreak of COVID-19 and its subsequent impact on restrictions on trade and movement of goods has resulted in a the closing of vast portions of the global economy, which has eventually resulted in disrupted supply chains due to limited materials and workforce, and slowdown or stopping of manufacturing. Moreover, several manufacturing facilities are focused on priority manufacturing to produce other essential medical supplies and equipment such as ventilators in the beginning of the emergency. The trade restrictions have impacted the market inversely. During the pandemic, as the demand increases, counterfeiting and price gouging of imported devices increase as well.

Furthermore, the proliferation of coronavirus has harmed patients willingness and ability to participate in clinical trials for new medicines. One of the most important blows to the CLLL drugs market has been COVID-19's interference with research and development of new treatments.

Due to the coronavirus pandemic many pharmaceutical industries have suspended the clinical trials. In a study it is estimated that approximately over 12,000 clinical trails are going on in the area of cancer. If these trails are stopped or suspended for any reason, it will have profound impact on the industry. Beyond this, loss of the potential health benefits for patients already enrolled in the trials, the cost of an oncology phase 3 clinical trial is on average at least USD 20 million, which will impose huge financial hurdle on companies for gaining approval for trail and identification for the patients for the second time.

According to, Centre for Drug Development (UK), the pandemic initially drew recruitment for UK clinical trials to an almost complete pause. From about April, 2020 until July or August 2020, all British hospitals stopped recruiting patients into new clinical trials, and they even stopped treating some patients already in clinical trials, if the visits weren't deemed completely necessary – so clinical development definitely had to pause in the year 2020. There was also a complete block on opening new trials as well. 

According to a survey published in Nature Reviews Drug Discovery by the Cancer Research Institute and IQVIA, patient enrolment in oncology clinical trials was significantly impacted in the early stages of the pandemic in the United States and Europe, with 60 percent and 86 percent of institutions respectively enrolling new patients at a lower rate.  Concerns over patients’ risk of contracting the virus, access, and the types of treatments being trialed – intravenous drugs, for example, cannot be administered at home were the main obstacles to enrolment in trials.

As a result of these barriers, 73% of the clinical trial investigators surveyed reported that they were avoiding or planning to avoid immunosuppressive treatment regimens, while 64% were shipping or planning to ship oral drugs directly to patient’s homes.

Surveyed investigators also expressed concern over the risk of missing or delayed data collection from disrupted ongoing trials, while analysis of data from ClinicalTrials.gov also indicated that over 200 interventional oncology studies were suspended because of COVID-19 between March and April of 2020.

Pharmaceutical businesses are using technology such as telecommunication, mobile applications, webinars, and other forms of digital media to satisfy the needs of patients during the pandemic. EDetailing is one such programme that promotes coordination between healthcare practitioners and patients, hence improving relationships.

Product Information Management (PIM) solutions is another such initiative. A Product Information Management (PIM) facilitates automation by offering a platform for all stakeholders, including patients and professionals, to gain visibility across the supply chain. Because the data is stored on a single digital platform, the danger of human error in reporting and updates is eliminated. Utilization of existing technology to make the processes efficient is expected to help pharmaceutical companies during the pandemic as well as post pandemic.

As the patients are afraid of getting infected and transportation facilities are drastically disrupted the demand of blood cancer drugs are affected by the coronavirus pandemic. As a result of COVID-19, social distance is increasing, and fewer patients are visiting the cancer clinics, causing delays in elective surgeries. As a result, the demand for drug delivery via online channels is growing.

About Us:

DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year, we have secured more than 100 unique customers from established organizations all over the world.

For more information:

Sai Kiran

Sales Manager at DataM Intelligence

Email: [email protected]

Tel: +1 877 441 4866

Website: www.datamintelligence.com